Can the shingles vaccine slow ageing?
The Economist
February 13, 2026
AI-Generated Deep Dive Summary
The shingles vaccine may hold unexpected benefits in slowing age-related decline. Recent evidence suggests that it reduces the risk of age-related health issues by 20% across various countries. This groundbreaking finding highlights a potential new tool in combating aging and its associated ailments.
Shingles, caused by reactivation of the herpes zoster virus, is more common among older adults due to weakened immune systems. The vaccine targets this virus, but its benefits extend beyond preventing shingles. Studies indicate it may also reduce chronic inflammation and organ function decline, which are linked to aging. This connection suggests that vaccines could play a broader role in promoting health in older populations.
The implications for public health and healthcare costs are significant. By slowing age-related diseases, the shingles vaccine could reduce hospital admissions and long-term care expenses. Businesses, particularly those in healthcare and pharmaceuticals, may see opportunities in expanding vaccination programs or developing similar interventions. For individuals, this could mean extended healthy aging and improved quality of life.
For businesses, understanding these connections can drive innovation and cost-saving measures. Employers might prioritize employee health initiatives that include vaccinations to reduce long-term healthcare expenses. Policymakers are also considering how to integrate such findings into national health strategies to maximize public benefit.
Overall, the potential for vaccines like the shingles shot to influence aging is a promising development in both health science and economic strategy. It underscores the importance of investing in preventive measures that address multiple age-related conditions simultaneously.
Verticals
businesseconomics
Originally published on The Economist on 2/13/2026